Edison

OSE Immunotherapeutics (PA:OSE) now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a key catalyst and due in Q120. Another three...

On 28 September 2019, Oryzon (MC:ORY) presented additional data from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, at the ESMO congress in Barcelona. A poster...

Flatex (after its online brokerage brand; previously FinTech) reported a 10% y-o-y increase in revenue in H119. Earnings fell 9% y-o-y to €8.6m (ROE 10.8%) but were +5% y-o-y after adjusting for...

H119 has seen PPHE Hotel Group Ltd (LON:PPH) again deliver both operationally and from a property perspective. Like-for-like EBITDA increased by 6%, driven by London, its main profit...

Carbios (PA:ALCRB)’s H119 results confirmed that the business is on a sound financial footing and continues to make progress towards the commercialisation of its technology. Commercial...

BioPharma Credit (LON:BPCR) (BPCR) has recently entered into an agreement to provide up to US$82.5m in the form of a five-year senior secured loan to OptiNose, a Nasdaq-listed, commercial-stage pharma...

S&U: The H120 results confirmed encouraging trends at Advantage motor finance with a resumption of growth in new transactions and an increase in receivables following a contraction in H219. Early...

Aberdeen Diversified Income and Growth Trust (Aberdeen Diversified Income and Growth Trust PLC (LON:ADIG)) continues to progress towards full implementation of its strategy, aiming to achieve...

PowerHouse Energy Group plc (LON:PHEG)’s interim results include news that its partner Peel Environmental has submitted the planning application for a waste-to-energy plant on its Protos Energy...

Ernst Russ’s (ERAG) strategic process of repositioning to focus on its investor and asset manager activities in the shipping and real estate segments was borne out in the H1 results. Increased...